Clinical Research Associate
Monte Rosa Therapeutics
Clinical Research Associate
Monte Rosa Therapeutics
Develops targeted protein degraders for therapy
The Clinical Research Associate (CRA) supports clinical trial quality, compliance, and execution through site monitoring, study startup, data oversight, and regulatory documentation. The CRA will also serve as an in-house sponsor representative overseeing CROs and third-party monitoring vendors, ensuring delegated activities meet protocol, GCP, quality, and timeline requirements. This role will be supporting Phase I-III clinical trials , the ideal candidate will have experience in Oncology indications or I &I. The CRA will have the ability to work Hybrid work arrangement with Boston office MRTx requires a 70% office presence. .Availability for approximately 30–40% travel is required for site visits, co-monitoring, investigator meetings, and select international activities.
Compensation: 95000 to 125000 (USD)
Develops targeted protein degraders for therapy
Monte Rosa Therapeutics develops molecular glue degraders (MGDs) to treat cancer and autoimmune/inflammatory diseases using its QuEEN discovery engine, a platform that fuses AI-guided chemistry, proteomics, and structural biology to design MGDs. MGDs work by bringing a target protein together with an E3 ligase, tagging the protein for destruction by the cell's proteasome rather than just inhibiting it. The company distinguishes itself with the QuEEN platform, partnerships with Roche and Novartis for joint development and funding, and a portfolio that includes MRT-2359, MRT-6160, and MRT-8102 as clinical-stage programs. Its goal is to discover, develop, and commercialize MGDs, grow its pipeline, and create value through collaborations, upfront payments, milestones, and royalties while delivering treatments for patients with serious diseases.
Explore more opportunities at Monte Rosa Therapeutics